NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

復發性心包膜炎 - 市場洞察,流行病學,市場預測 2028年

Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 773927
出版日期 按訂單生產 內容資訊 英文 85 Pages
商品交期: 2-10個工作天內
價格
復發性心包膜炎 - 市場洞察,流行病學,市場預測 2028年 Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028
出版日期: 按訂單生產內容資訊: 英文 85 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的復發性心包膜炎市場調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數·罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 簡介

第2章 復發性心包膜炎市場概要

  • 復發性心包膜炎的市場佔有率(實際成果值)
  • 復發性心包膜炎的市場佔有率(預測值)

第3章 疾病背景和概要:復發性心包膜炎

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的復發性心包膜炎的整體患病數/罹患數
  • 主要7個國家的復發性心包膜炎的整體患病數:各國

第5章 復發性心包膜炎的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 復發性心包膜炎的患病數/罹患數
    • 復發性心包膜炎的病例數:病型
    • 復發性心包膜炎的病例數:性別
    • 復發性心包膜炎的診斷數
    • 復發性心包膜炎的可治療病例數
  • 歐盟5國
    • 假設和理論的根據
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 已上市治療藥

  • 醫藥品 A:製藥企業
    • 醫藥品概要
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 產品簡介
  • 醫藥品 B:製藥企業

第9章 開發平台治療藥

第10章 主要交叉競爭

第11章 復發性心包膜炎的新藥

  • 醫藥品 C:製藥企業
    • 藥的說明
    • 臨床試驗詳細內容
    • 安全性和有效性的簡介
    • 優點與缺點
    • 開發平台開發活動
    • 產品簡介
  • 醫藥品 D:製藥企業

第12章 復發性心包膜炎:主要7個國家的市場分析

  • 復發性心包膜炎的市場規模
  • 復發性心包膜炎的已上市治療藥的佔有率
  • 復發性心包膜炎的治療藥的銷售額:各產品

第13章 復發性心包膜炎:各國市場分析

  • 美國
    • 復發性心包膜炎的市場規模
    • 復發性心包膜炎的已上市治療藥的市場佔有率
    • 復發性心包膜炎的治療藥的銷售額:各產品
    • 新藥分析和對市場的影響
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 調查方法

  • 出處

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0503

DelveInsight's 'Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Recurrent Pericarditis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Recurrent Pericarditis from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Recurrent Pericarditis - Disease Understanding

Pericarditis is an inflammation of the pericardium which is usually acute, developing suddenly and may last up to several months. It may have infectious or non-infectious causes, and is manifested by a combination or signs (i.e., pericardial rubs, electrocardiographic changes and pericardial effusion), symptoms (mainly chest pain but possible additional symptoms such as dyspnea) and usually elevation of markers of myocardial inflammation (i.e., protein C reactive).

Recurrent Pericarditis is a pericardial syndrome in which signs and symptoms of pericardial inflammation may occur after a symptom-free interval of at least 4-6 weeks following an episode of acute pericarditis. It is by far the most troublesome complication of acute pericarditis occurring within 18 months in 30% (20% to 50%) of patients after the first episode of acute pericarditis as it can lead to repeated hospitalizations, additional treatment costs, and development of cardiac tamponade or, more rarely, constrictive pericarditis in some patients Imazio M et al. 2017. Diagnosis of recurrence is established according to the same criteria as those used for acute pericarditis.

The DelveInsight Recurrent Pericarditis market report gives a thorough understanding of the Recurrent Pericarditis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Recurrent Pericarditis in the US, Europe, and Japan.

Recurrent Pericarditis Epidemiology

The Recurrent Pericarditis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by incident population, gender-specific diagnosed incident population and age-specific diagnosed incident population of Recurrent Pericarditis.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the incident population of Recurrent Pericarditis was estimated to be 46827 [7MM] in 2018. United States accounts for the highest Recurrent Pericarditis cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Recurrent Pericarditis, followed by France.

Recurrent Pericarditis Management

The therapies which are currently used to manage recurrent pericarditis are: NSAIDs/aspirin, colchicine, Corticosteroids, Immunosuppressors, Azathioprine and other immunosuppressive therapies, Immunomodulators (Intravenous immunoglobulin, Anakinra) and Pericardiectomy.

Recurrent Pericarditis Market Outlook

The Recurrent Pericarditis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Recurrent Pericarditis was estimated to be USD 77.04 million in 2018. The United States accounts for the largest market size of Recurrent Pericarditis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size worth USD 9.56 million in 2018, while Spain had the lowest market size of Recurrent Pericarditis valued at USD 3.16 million in 2018.

The dynamics of Recurrent Pericarditis market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Amongst the therapeutic lines of therapy (LoTs), the 1st LoT is believed to hold the highest patient share [%] amongst all other therapeutic options available for the treatment of Recurrent Pericarditis.

Recurrent Pericarditis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Recurrent Pericarditis includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

Expected launch of potential therapies will lead to an increase in the market size of Recurrent Pericarditis in the coming years. Rilonacept (Kiniksa Pharmaceuticals, Ltd.) is the first immunosuppressant that is expected to be launched in all of the 7 Major Markets, during the forecast period [2019-2028].

Recurrent Pericarditis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Recurrent Pericarditis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Recurrent Pericarditis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Recurrent Pericarditis market.
  • Organize sales and marketing efforts by identifying the best opportunities for Recurrent Pericarditis market.
  • To understand the future market competition in the Recurrent Pericarditis market.

Table of Contents

1 Key Insights

2 Recurrent Pericarditis Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of Recurrent Pericarditis in 2016
  • 2.2 Market Share (%) Distribution of Recurrent Pericarditis in 2027

3 Recurrent Pericarditis: Disease Background and Overview

  • 3.1 Introduction
    • 3.1.1 Pericardium
  • 3.2 Signs and Symptoms of Recurrent Pericarditis
  • 3.3 Etiology and Causes
    • 3.3.1 Bacterial infections
    • 3.3.2 Viral etiology
    • 3.3.3 Neoplastic Pericarditis
    • 3.3.4 Systemic Diseases
    • 3.3.5 Postcardiac Injury Syndromes
    • 3.3.6 Drug-induced pericarditis
  • 3.4 Pathogenesis
  • 3.5 Diagnosis of Recurrent Pericarditis

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2 Population and Forecast Parameters
  • 4.3 Total Incidence of Recurrent Pericarditis in 7MM

5 Country Wise-Epidemiology of Recurrent Pericarditis

6 United States

  • 6.1 Assumptions and Rationale
  • 6.2 Incident Population of Recurrent Pericarditis in the United States
  • 6.3 Gender Specific Incidence of Recurrent Pericarditis in the US
  • 6.4 Age Specific Incidence of Recurrent Pericarditis in the US

7 EU-5

  • 7.1 Assumptions and Rationale

8 Germany

  • 8.1 Incident Population of Recurrent Pericarditis in Germany
  • 8.2 Gender-specific Incidence of Recurrent Pericarditis in Germany
  • 8.3 Age-Specific Incidence of Recurrent Pericarditis in Germany

9 France

  • 9.1 Incident Population of Recurrent Pericarditis in France
  • 9.2 Gender-specific Incidence of Recurrent Pericarditis in France
  • 9.3 Age-Specific Incidence of Recurrent Pericarditis in France

10 Italy

  • 10.1 Incident Population of Recurrent Pericarditis in Italy
  • 10.2 Gender-specific Incidence of Recurrent Pericarditis in Italy
  • 10.3 Age-Specific Incidence of Recurrent Pericarditis in Italy

11 Spain

  • 11.1 Incident Population of Recurrent Pericarditis in Spain
  • 11.2 Gender-specific Incidence of Recurrent Pericarditis in Spain
  • 11.3 Age-Specific Incidence of Recurrent Pericarditis in Spain

12 United Kingdom

  • 12.1 Incident Population of Recurrent Pericarditis in the United Kingdom
  • 12.2 Gender-specific Incidence of Recurrent Pericarditis in the United Kingdom
  • 12.3 Age-Specific Incidence of Recurrent Pericarditis in the UK

13 Japan

  • 13.1 Assumptions and Rationale
  • 13.2 Incident Population of Recurrent Pericarditis in Japan
  • 13.3 Gender-specific Incidence of Recurrent Pericarditis in Japan
  • 13.4 Age-Specific Incidence of Recurrent Pericarditis in Japan

14 Treatment of Recurrent Pericarditis

  • 14.1 Current Treatment Practices
  • 14.2 Therapeutic methods
    • 14.2.1 NSAIDs/aspirin
    • 14.2.2 Colchicine
    • 14.2.3 Corticosteroids
    • 14.2.4 Immunosuppressors
    • 14.2.5 Azathioprine and other immunosuppressive therapies
    • 14.2.6 Immunomodulators
    • 14.2.7 Pericardiectomy

15 Unmet Needs

16 Emerging Therapies

  • 16.1 Emerging Drugs Analysis
  • 16.2 Rilonacept: Kiniksa Pharmaceuticals, Ltd.
    • 16.2.1 Product Description
    • 16.2.2 Regulatory Milestones
    • 16.2.3 Clinical Development
    • 16.2.4 Safety and Efficacy
    • 16.2.5 Product Profile

17 Recurrent Pericarditis: 7 Major Market Analysis

  • 17.1 Key Findings
  • 17.2 Total Market Size of Recurrent Pericarditis in 7MM

18 Market Outlook by Country

  • 18.1 The United States: Market Outlook
  • 18.2 United States Market Size
    • 18.2.1 Total Market size of Recurrent Pericarditis
    • 18.2.2 Recurrent Pericarditis Market Size by Line of Therapies
  • 18.3 EU-5 Countries: Market Outlook
  • 18.4 Germany Market Size
    • 18.4.1 Total Market Size of Recurrent Pericarditis
    • 18.4.2 Recurrent Pericarditis Market Size by Line of Therapies
  • 18.5 France Market Size
    • 18.5.1 Total Market Size of Recurrent Pericarditis
    • 18.5.2 Recurrent Pericarditis Market Size by Line of Therapies
  • 18.6 Italy Market Size
    • 18.6.1 Total Market Size of Recurrent Pericarditis
    • 18.6.2 Recurrent Pericarditis Market Size by Line of Therapies
  • 18.7 Spain Market Size
    • 18.7.1 Total Market size of Recurrent Pericarditis
    • 18.7.2 Recurrent Pericarditis Market Size of Line of Therapies
  • 18.8 The United Kingdom Market Size
    • 18.8.1 Total Market Size of Recurrent Pericarditis
    • 18.8.2 Recurrent Pericarditis Market Size by Line of Therapies
  • 18.9 Japan: Market Outlook
  • 18.1 Japan: Market Size
    • 18.10.1 Total Market Size of Recurrent Pericarditis
    • 18.10.2 Recurrent Pericarditis Market Size by Line of Therapies

19 Market Drivers

20 Market Barriers

21 Appendix

22 Report Methodology

  • 22.1 Sources Used

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

List of Tables

  • Table 1: Total Incident Population of Recurrent Pericarditis in 7MM (2016-2027)
  • Table 2: Incident Population of Recurrent Pericarditis in the United States (2016-2027)
  • Table 3: Gender specific Incidence of Recurrent Pericarditis in the US [2016-2027]
  • Table 4: Age-Specific Incidence of Recurrent Pericarditis in the United States (2016-2027)
  • Table 5: Incident Population of Recurrent Pericarditis in Germany (2016-2027)

Table 6 Gender-specific Incidence of Recurrent Pericarditis in Germany (2016-2027)

  • Table 7: Age-Specific Incidence of Recurrent Pericarditis in Germany (2016-2027)
  • Table 8: Incident Population of Recurrent Pericarditis in France (2016-2027)

Table 9 Gender-specific Incidence of Recurrent Pericarditis in France (2016-2027)

  • Table 10: Age-Specific Incidence of Recurrent Pericarditis in France (2016-2027)
  • Table 11: Incident Population of Recurrent Pericarditis in Italy (2016-2027)

Table 12 Gender-specific Incidence of Recurrent Pericarditis in Italy (2016-2027)

  • Table 13: Age-Specific Incidence of Recurrent Pericarditis in Italy (2016-2027)
  • Table 14: Incident Population of Recurrent Pericarditis in Spain (2016-2027)

Table 15 Gender-specific Incidence of Recurrent Pericarditis in Spain (2016-2027)

  • Table 16: Age-Specific Incidence of Recurrent Pericarditis in Spain (2016-2027)
  • Table 17: Incident Population of Recurrent Pericarditis in the United Kingdom (2016-2027)

Table 18 Gender-specific Incidence of Recurrent Pericarditis in the United Kingdom (2016-2027)

  • Table 19: Age-Specific Incidence of Recurrent Pericarditis in the UK (2016-2027)
  • Table 20: Incident Population of Recurrent Pericarditis in Japan (2016-2027)

Table 21 Gender-specific Incidence of Recurrent Pericarditis in Japan (2016-2027)

  • Table 22: Age-Specific Incidence of Recurrent Pericarditis in Japan (2016-2027)
  • Table 23: Tapering of corticosteroids
  • Table 24: The 2010 revised McDonald criteria for diagnosis of MS
  • Table 25: Medical Therapy for Pericarditis: Practical Scheme in the Clinical Setting
  • Table 26 : Recommendations for the management of recurrent pericarditis
  • Table 27: Rilonacept Clinical Trial Description, 2018
  • Table 28: 7 Major Market Size of Recurrent Pericarditis in USD Million (2016-2027)
  • Table 30: Market Size of Recurrent Pericarditis in the US, in USD Million (2016-2027)
  • Table 31: The US Recurrent Pericarditis Market Size by Line of Therapies in USD Million (2016-2027)
  • Table 32: Market Size of Recurrent Pericarditis in Germany, in USD Million (2016-2027)
  • Table 33: Market Size of Recurrent Pericarditis in Germany by Line of Therapies in USD Million (2016-2027)
  • Table 34: Market Size of Recurrent Pericarditis in France, in USD Million (2016-2027)
  • Table 35: Market Size of Recurrent Pericarditis in Germany by Line of Therapies in USD Million (2016-2027)
  • Table 36: Market Size of Recurrent Pericarditis in Italy, in USD Million (2016-2027)
  • Table 37: Market Size of Recurrent Pericarditis in Italy by Line of Therapies in USD Million (2016-2027)
  • Table 38: Market Size of Recurrent Pericarditis in Spain, in USD Million (2016-2027)
  • Table 39: Market Size of Recurrent Pericarditis in Spain by Line of Therapies in USD Million (2016-2027)
  • Table 40: Market Size of Recurrent Pericarditis in the UK, in USD Million (2016-2027)
  • Table 41: Market Size of Recurrent Pericarditis in the UK by Line of Therapies in USD Million (2016-2027)
  • Table 42: Market Size of Recurrent Pericarditis in Germany, in USD Million (2016-2027)
  • Table 43: Market Size of Recurrent Pericarditis in Germany by Line of Therapies in USD Million (2016-2027)

List of Figures

  • Figure 1: Pericarditis with a thickened pericardium
  • Figure 2: Echocardiographic semiquantitative assessment of pericardial effusion
  • Figure 3:Traditional electrocardiographic changes are characterised by diffuse ST elevation in Acute Pericarditis
  • Figure 4: Total Incident Population of Recurrent Pericarditis in 7 MM (2016-2027)
  • Figure 5: Incident Population of Recurrent Pericarditis in the United States (2016-2027)
  • Figure 6: Gender Specific Incidence of Recurrent Pericarditis in the United States (2016-2027)
  • Figure 7: Diagnosed/Treatable cases of Recurrent Pericarditis in the United States (2016-2027)
  • Figure 8: Incident Population of Recurrent Pericarditis in Germany (2016-2027)

Figure 9 Gender-specific Incidence of Recurrent Pericarditis in Germany (2016-2027)

  • Figure 10: Age-Specific Incidence of Recurrent Pericarditis in the Germany (2016-2027)
  • Figure 11: Incident Population of Recurrent Pericarditis in France (2016-2027)
  • Figure 12: Gender-specific Incidence of Recurrent Pericarditis in France (2016-2027)
  • Figure 13: Age-Specific Incidence of Recurrent Pericarditis in France (2016-2027)
  • Figure 14: Incident Population of Recurrent Pericarditis in Italy (2016-2027)
  • Figure 15: Gender-specific Incidence of Recurrent Pericarditis in Italy (2016-2027)
  • Figure 16: Age-Specific Incidence of Recurrent Pericarditis in Italy (2016-2027)
  • Figure 17: Incident Population of Recurrent Pericarditis in Spain (2016-2027)
  • Figure 18: Gender-specific Incidence of Recurrent Pericarditis in Spain (2016-2027)
  • Figure 19: Age-Specific Incidence of Recurrent Pericarditis in Spain (2016-2027)
  • Figure 20: Incident Population of Recurrent Pericarditis in the United Kingdom (2016-2027)
  • Figure 21: Gender-specific Incidence of Recurrent Pericarditis in the United Kingdom (2016-2027)
  • Figure 22: Age-Specific Incidence of Recurrent Pericarditis in the UK (2016-2027)
  • Figure 23: Incident Population of Recurrent Pericarditis in Japan (2016-2027)
  • Figure 24: Gender-specific Incidence of Recurrent Pericarditis in Japan (2016-2027)
  • Figure 25: Age-Specific Incidence of Recurrent Pericarditis in Japan (2016-2027)
  • Figure 26: Clinical Stages of Pericarditis With Imaging and Treatment Considerations
  • Figure 27: Therapeutic algorithm for acute and recurrent pericarditis
  • Figure 28: Unmet Needs for Recurrent Pericarditis
  • Figure 29: Analysis of Phase III Drug
  • Figure 30: 7 Major Market Size of Recurrent Pericarditis in USD Million (2016-2027)
  • Figure 32: Market Size of Recurrent Pericarditis in the United States, USD Millions (2016-2027)
  • Figure 33: The U.S. Recurrent Pericarditis Market Size by Line of Therapies in USD Million (2016-2027)
  • Figure 34: Market Size of Recurrent Pericarditis in Germany, USD Millions (2016-2027)
  • Figure 35: Germany Recurrent Pericarditis Market Size by Line of Therapies in USD Million (2016-2027)
  • Figure 36: Market Size of Recurrent Pericarditis in France, USD Millions (2016-2027)
  • Figure 37: France Recurrent Pericarditis Market Size by Therapies in USD Million (2016-2027)
  • Figure 38: Market Size of Recurrent Pericarditis in Italy, USD Millions (2016-2027)
  • Figure 39: Italy Recurrent Pericarditis Market Size by Therapies in USD Million (2016-2027)
  • Figure 40: Market Size of Recurrent Pericarditis in Spain, USD Millions (2016-2027)
  • Figure 41: Spain Recurrent Pericarditis Market Size by Therapies in USD Million (2016-2027)
  • Figure 42: Market Size of Recurrent Pericarditis in UK, USD Millions (2016-2027)
  • Figure 43: The UK Recurrent Pericarditis Market Size by Therapies in USD Million (2016-2027)
  • Figure 44: Market Size of Recurrent Pericarditis in Japan, USD Millions (2016-2027)
  • Figure 45: Japan Recurrent Pericarditis Market Size by Line of Therapies in USD Million (2016-2027)
  • Figure 46: Market Drivers of Recurrent Pericarditis
  • Figure 47:Market Barriers of Recurrent Pericarditis